Table 3.
Medical therapy at baseline in elderly and nonelderly patients with IPF.
| Age group <75 years n = 659 | Age group ≥75 years n = 350 | p-value | |
|---|---|---|---|
| Prednisone, n (%) | 136 (20.6) | 64 (18.3) | 0.372 |
| Other steroid, n (%) | 9 (1.4) | 8 (2.3) | 0.280 |
| Azathioprine, n (%) | 11 (1.7) | 3 (0.9) | 0.294 |
| Cyclophosphamide, n (%) | 1 (0.2) | 0 (0.0) | 0.466 |
| Mycophenolate mofetil, n (%) | 1 (0.2) | 0 (0.0) | 0.466 |
| N-Acetylcysteine, n (%) | 144 (21.9) | 69 (19.7) | 0.429 |
| Other, n (%) | 16 (2.4) | 9 (2.6) | 0.889 |
| Anticoagulation–prophylactic, n (%) | 51 (7.8) | 57 (16.3) | <0.001 |
| Anticoagulation–therapeutic, n (%) | 63 (9.6) | 66 (18.9) | <0.001 |
| Pirfenidone, n (%) | 256 (38.9) | 112 (32.0) | 0.032 |
| Nintedanib, n (%) | 119 (18.1) | 82 (23.4) | 0.042 |
| Antifibrotic therapy (nintedanib or pirfenidone), n (%) | 374 (56.8) | 194 (55.4) | 0.687 |
| Long-term oxygen therapy, n (%) | 200 (30.4) | 109 (31.1) | 0.795 |
Data are presented as n (%).